PUBLICATIONS

Publications, Projects & Awards

Organized by program & group, as selected by each corresponding VHIO Principal Investigator

(Please click on the corresponding programs below)

Experimental Therapeutics Group / Violeta Serra

Imagen

Principal Investigator
Violeta Serra

Medical Oncologists
Cristina Cruz
Jordi Rodón

Post-Doctoral Fellows
Alba Llop
Marta Palafox

Graduate Students
Marta Castroviejo
Albert Gris

Technicians
María Teresa Calvo
Judit Grueso
Marta Guzmán
Olga Rodríguez

Publications / Experimental Therapeutics Group

  1. MEK plus PI3K/mTORC1/2 therapeutic efficacy is impacted by TP53 mutation in preclinical models of colorectal cancer. García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodriguez O, Grueso J, Anton P, Guzman M, Aura C, Nuciforo P, Jessen K, Argiles G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. Clin Cancer Res. 2015 Dec 15;21(24):5499-510.
  2. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. Sci Transl Med. 2015 Apr 15;7(283):283ra51.
  3. Targeting a cell state common to triple-negative breast cancers. Muellner MK, Mair B, Ibrahim Y, Kerzendorfer C, Lechtermann H, Trefzer C, Klepsch F, Müller AC, Leitner E, Macho-Maschler S, Superti-Furga G, Bennett KL, Baselga J, Rix U, Kubicek S, Colinge J, Serra V, Nijman SM. Mol Syst Biol. 2015 Feb 19;11:789.

Projects / Experimental Therapeutics Group

  1. Targeting PI3K and CDK4/6 in breast cancer: Integrative Biomarkers of Response
    (CCR15330331)
    Principal Investigator: Violeta Serra
    Funding Agency: Susan G Komen Foundation
    Duration: 2015-2018
  2. Targeting PI3K and CDK4/6 in breast cancer
    (CP14/00028)
    Principal Investigator: Violeta Serra
    Funding Agency: ISCIII (Spanish Ministry of Health)
    Duration: 2015-2019
  3. TInhibition of PI3K in breast cancer: in-depth analysis of the predictive factors and rational design of therapeutic combinations
    (PI13/01704)
    Principal Investigator: Violeta Serra
    Funding Agency: ISCIII (Spanish Ministry of Health)
    Duration: 2014-2016
  4. Translational research on human tumor heterogeneity to overcome recurrence and therapy
    Research Partner PI: Violeta Serra
    Funding Agency: ERA-NET
    Duration: 2015-2017
  5. Acknowledged Emerging Research Group (SGR): Experimental Therapeutics in Breast Cancer
    (2014-SGR-1331)
    Group Coordinator: Violeta Serra
    Funding Agency: AGAUR (Catalan Agency for Research)
    Duration: 2014-2016
  1. Genetic determinants of sensitivity to PARP and Wee1 inhibitors in breast cancer and Genetic determinants of Wee1 inhibitors in TNBC
    Principal Investigator: Violeta Serra
    Funding Pharma: AstraZeneca
    Duration: 2014-2015
  2. Defining clinically actionable genetic alterations in DNA repair with in vivo response to the PARP inhibitor olaparib
    Principal Investigators: Violeta Serra, Joan Seoane, and Héctor G. Palmer
    Funding Pharma: AstraZeneca - Spain
    Duration: 2014-2015
  3. Anti-tumor activity of PM01183 in olaparib resistant patient-derived tumor xenografts with BRCA mutation
    Principal Investigator: Judith Balmaña
    Funding Pharma: Pharmamar
    Duration: 2014-2015
  4. Novel strategies in the breast cancer treatment: PI3K inhibitors and Rational design of combined therapy with PI3K inhibitors in breast cancer
    Principal Investigators: Violeta Serra and José Baselga
    Funding Agencies: GHD / FERO Foundation
    Duration: 2012-2015

Awards / Experimental Therapeutics Group

Miguel Servet Researcher, Instituto de Salud Carlos III (ISCIII)

Growth Factors Group / Joaquín Arribas

Imagen

Principal Investigator
Joaquín Arribas

Medical Oncologist
César Serrano

Post-Doctoral Fellows
Cristina Bernadó
Águeda Martínez Barriocanal
Beatriz Morancho
Kim Pedersen
Verónica Rodilla
Mariano F. Zacarías

Graduate Students
Faiz Bilal
Irene Rius
Rocío Vicario

Technicians
Marta Escorihuela
Cristina Ferrer
Mariona Gelabert
Antoni Luque
David Olivares

PhD Student
Junjie Zhang

Publications / Growth Factors Group

  1. Morancho B, Martínez-Barriocanal Á, Villanueva J, Arribas J. Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence. Breast Cancer Res. 2015 Aug 12;17:106.
  2. Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortés J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS One. 2015 Jun 15;10(6):e0129876.
  3. Zacarias-Fluck MF, Morancho B, Vicario R, Luque Garcia A, Escorihuela M, Villanueva J, Rubio IT, Arribas J. Effect of cellular senescence on the growth of HER2-positive breast cancers. J Natl Cancer Inst. 2015 May 13;107(5).
  4. Massó-Vallés D, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, Whitfield JR, Beaulieu ME, Evan GI, Elias L, Arribas J, Soucek L. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res. 2015 Apr 15;75(8):1675-81.
  5. Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart M, Baselga J. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res. 2015 Feb 1;21(3):569-76.

Mouse Models of Cancer Therapies Group / Laura Soucek

Imagen

Principal Investigator
Laura Soucek

Staff Scientist
Jonathan Whitfield

Post-Doctoral Fellow
Marie-Eve Beaulieu

Graduate Students
Toni Jauset González
Sandra Martínez
Daniel Massó Vallés

Technician
Érika Serrano del Pozo

Publications / Mouse Models of Cancer Therapies Group

  1. Live or Die: Choice Mechanisms in Stressed Cells. Cecconi F, Soucek L, Taub DD, Ziparo E. Mediators Inflamm. 2015;2015:454863. doi: 10.1155/2015/454863. Epub 2015 Oct 8.
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609861/pdf/MI2015-454863.pdf
  2. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP Sr, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z. Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96. doi: 10.1093/carcin/bgv039.
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480130/pdf/bgv039.pdf
  3. The effect of environmental chemicals on the tumor microenvironment. Casey SC, Vaccari M, Al-Mulla F, Al-Temaimi R, Amedei A, Barcellos-Hoff MH, Brown DG, Chapellier M, Christopher J, Curran CS, Forte S, Hamid RA, Heneberg P, Koch DC, Krishnakumar PK, Laconi E, Maguer-Satta V, Marongiu F, Memeo L, Mondello C, Raju J, Roman J, Roy R, Ryan EP, Ryeom S, Salem HK, Scovassi AI, Singh N, Soucek L, Vermeulen L, Whitfield JR, Woodrick J, Colacci A, Bisson WH, Felsher DW. Carcinogenesis. 2015 Jun;36 Suppl 1:S160-83. doi: 10.1093/carcin/bgv035.
    http://carcin.oxfordjournals.org/content/36/Suppl_1/S160.full.pdf+html
  4. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Massó-Vallés D, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, Whitfield JR, Beaulieu ME, Evan GI, Elias L, Arribas J, Soucek L. Cancer Res. 2015 Apr 15;75(8):1675-81. doi: 10.1158/0008-5472.CAN-14-2852.
    http://cancerres.aacrjournals.org/content/75/8/1675.full.pdf+html
  5. The estrogen receptor fusion system in mouse models: a reversible switch. Whitfield J, Littlewood T, Evan GI, Soucek L.Cold Spring Harb Protoc. 2015 Mar 2;2015(3):227-34. doi: 10.1101/pdb.top069815. PMID: 25734072
  6. Tamoxifen administration to mice. Whitfield J, Littlewood T, Soucek L. Cold Spring Harb Protoc. 2015 Mar 2;2015(3):269-71. doi: 10.1101/pdb.prot077966. PMID: 25734062

Awards / Mouse Models of Cancer Therapies Group

  1. The Soucek laboratory was awarded a BBVA Foundation Grant in Biomedicine. Title: Validation of an innovative anti-Myc therapy in glioblastoma
  2. The group was also awarded first prize in the Competition for Innovation by the Vall d´Hebron Institute of Research (VHIR), Barcelona, Spain. Title: Pushing Myc inhibition to the clinic using cell penetrating peptides. The project aims at developing a new therapeutic option for patients with cancer by targeting the Myc protein with an inhibitor peptide, Omomyc, a new pharmaceutical entity.
  3. Peptomyc was awarded a ´Seal of Excellence´ for an SME Instrument Phase I by the European Commission within the Horizon2020 Program.
  4. Laura was awarded a FERO fellowship for a nanotechnology project aiming at treating metastatic breast cancer with Omomyc-based nanoparticles.
  5. Marie-Eve Beaulieu, postdoctoral fellow in our lab, was awarded a prize for the best presentation at the 15th ASEICA International Congress (Seville, Spain, 21 – 23 October).
  6. Jonathan Whitfield, Staff Scientist in the Soucek lab, was awarded a fellowship to attend and present at the joint VHIO/Weizmann Institute of Science Joint Conference on Cell Communication in Translational Research, 22 – 23 January, 2015, Rehovot, Israel
  7. Daniel Massó, PhD student in the laboratory, was awarded best poster prize at the 9th Scientific Session of the Vall d’Hebron Research Institute (VHIR). Title: Targeting Myc in Breast Cancer Metastasis.
  8. Toni Jauset, PhD student in the laboratory, was awarded the poster prize at XII Scientific Session of Biochemistry and Molecular Biology of Universidad Autónoma de Barcelona. Title: Myc inhibition is an effective strategy against multiple subtypes of NSCLC.

Laura Soucek is currently a Reviewer for Anti-cancer Drugs, BBA (Biochimica et Biophysica Acta), BioEssays, Cancer Immunology and Immunotherapy, Cancer Research, Cancer Treatment Review, Clinical Cancer Research, Current Pharmaceutical Design, Developmental Dynamics, Drug Discovery Today, Gastroenterology Research and Practice, International Journal of Biological Sciences, IJEP (International Journal of Experimental Pathology), Journal of Experimental and Clinical Cancer Research, Molecular Biology and Evolution, Nature, Nature Cell Biology, Nature Communications, Nature Medicine, Oncogene, Oncogenesis, “Oncology” books, iConcept Press Ltd, Plos One, Therapeutic Advances in Chronic Disease, Tumor Biology. Laura Soucek is currently a Scientific Editor for the journal Cancer Discovery.

VHIO´s Mouse Models of Cancer Therapies in the media: examples of National and International news coverage:

Laura and her group also featured in the annual FERO Foundation´s video, presented at the annual FERO fundraising dinner in Barcelona:

Special coverage of the FERO video in the Spanish periodical La Vanguardia:

Tumor Biomarkers Group / Josep Villanueva

Imagen

Principal Investigator
Josep Villanueva

Post-Doctoral Fellows
Mercè Juliachs
Olga Méndez

Technician
Mireia Pujals

Publications / Tumor Biomarkers Group

  1. Méndez O, Villanueva J.Challenges and opportunities for cell line secretomes in cancer proteomics. Proteomics Clin Appl. 2015, Apr;9(3-4):348-57. doi: 10.1002/prca.201400131. Epub 2015 Feb 10. Review.
  2. Zacarias Fluck M, Morancho B, Vicario R, Luque-García A, Ferrer-Ramón C, Escorihuela M, Villanueva J, Rubio I, Arribas J. Cellular senescence supports the growth of HER2-positive breast cancers. J Natl Cancer Inst. 2015 May 13;107(5). pii: djv020. doi: 10.1093/jnci/djv020.
  3. Morancho B, Martínez-Barriocanal Á, Villanueva J, Arribas J. Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence. Breast Cancer Res. 2015 Aug 12;17:106. doi: 10.1186/s13058-015-0619-7.

Projects / Tumor Biomarkers Group

  1. Tumor Invasion-based Secretomes for Cancer Biomarker Discovery
    Agency: SNS FIS
    Duration: 01/01/2013 - 31/12/2015
    Principal Investigator: Josep Villanueva
  1. Diagnostic and Therapeutic implications of extracellular HMGA1 in Breast Cancer
    Agency : Susan G Komen
    Duration: 15/09/2015 - 15/09/2017
    Principal Investigator: Josep Villanueva